Please note that not all cases of disease or outbreaks are reported; some outbreaks may only be reported if they occur outside of the usual recognised risk area or season, or they have been reported in greater than usual numbers. See 'About Outbreaks' tab below for further detail.
For further information on red, amber and green alert categories, see About Outbreaks tab.
Mpox in Burundi
As of 12 October 2025, a total of 4,495 clade Ib mpox cases, with one death, have been reported in Burundi since 2024. Please see our Topics in Brief article for further details on mpox.
As of 31 July 2025, a total of 4,231 mpox clade Ib cases, with one death, have been confirmed in Burundi since 2024. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 22 June 2025, a total of 4,025 mpox clade Ib cases and one death have been reported in Burundi since January 2024. Community transmission of clade Ib mpox has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 25 May 2025, a total of 3,934 confirmed mpox cases and one confirmed death have been reported in Burundi since 2024. Community transmission of clade Ib mpox has been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 27 April 2025, a total of 3,835 confirmed mpox cases have been reported since the outbreak began in 2024. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 1 April 2025, a total of 3,714 mpox cases have been reported since January 2024. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 16 March 2025, 3,645 confirmed mpox cases including one death have been reported in Burundi. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 2 March 2025, a total of 3,586 confirmed mpox cases and one death have been reported in Burundi since the outbreak started in 2024. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 23 February 2025, a total of 3,543 confirmed mpox cases have been reported in Burundi since the outbreak started in 2024. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 16 February 2025, a total of 3,463 confirmed mpox cases have been reported in Burundi. Mpox clade Ib has been reported. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 2 February 2025, a total of 3,359 confirmed mpox cases and 45 deaths have been reported in Burundi. Clade Ib mpox has been isolated from confirmed cases. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 26 January 2025, a total of 3,242 confirmed cases of clade Ib mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 12 January 2025, a total of 3,116 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 5 January 2025, a total of 3,035 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 22 December 2024, a total of 2,861 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 15 December 2024, a total of 2,650 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 8 December 2024, a total of 2,523 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 1 December 2024, a total of 2,334 confirmed cases of mpox and one death have been reported in Burundi. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 20 November 2024, Burundi has reported 2,050 confirmed mpox clade Ib cases, with one death, in 2024. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 14 November 2024, Burundi has reported 1,863 confirmed mpox clade Ib cases and no deaths during 2024. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 3 November 2024, Burundi has reported 1,726 mpox clade Ib cases and 0 deaths during 2024. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 27 October 2024, a total of 1,509 clade Ib mpox cases have been reported in 2024. No mpox deaths have currently been reported for 2024. Please see our Topics in Brief article for further details on mpox.
Source: WHOAs of 20 October 2024, a total of 1,287 clade Ib mpox cases have been reported in 2024. No mpox deaths have currently been reported for 2024.
Source: WHOAs of 13 October 2024, the World Health Organization have reported 1,169 cases of mpox clade Ib during 2024.
Source: WHOAs of 6 October 2024, the World Health Organization have reported a total of 987 clade Ib mpox cases in Burundi for 2024.
Source: WHOAs of 1 October 2024, a total of 853 clade Ib mpox cases have been reported in 2024. No mpox deaths have currently been reported for 2024.
Source: WHOAs of 22 September 2024, a total of 696 clade Ib mpox cases have been reported in 2024. No mpox deaths have currently been reported for 2024.
Source: WHOAs of 15 September 2024, a total of 564 clade Ib mpox cases have been reported in 2024. No mpox deaths have currently been reported for 2024.
Source: WHOAs of 12 September 2024, a total of 385 confirmed cases of clade Ib mpox have been reported, with no deaths.
Source: WHOAs of 5 September 2024, 328 confirmed cases of clade Ib mpox have been reported. No deaths have been reported.
Source: WHOOn 29 August 2024, the WHO provided an update on countries that have so far reported clade Ib mpox cases. Burundi is the most affected country outside of the Democratic Republic of the Congo with 258 confirmed cases distributed across the country. No deaths have been reported.
Source: WHOAs of 13 August 2024, a total of 100 confirmed mpox cases have been reported from 23 health districts in Burundi. Clade Ib mpox cases have been confirmed.
Source: StateOn 4th August the Ministry of Public Health reported they had registered 37 confirmed cases of mpox since 25 July 2024. Confirmed cases were reported from 16 of the 49 health districts.
Source: StateDengue in Cook Islands
As of 15 October 2025, a total of 174 dengue cases have been reported on the Cook Islands since February 2025. DENV-1 and DENV-2 are reported to be co-circulating. Please see our Topics in Brief article for further details on dengue.
As of 18 August 2025, a total of 93 confirmed cases of dengue cases have been reported on Rarotonga, Cook Islands, since February 2025. Of the 50 confirmed serotypes, 47 were DENV-1 and three were DENV-2. Please see our Topics in Brief article for further details on dengue.
Source: ReliefWebAs of 7 July 2025, a total of 55 dengue cases (28 confirmed) have been reported on Rarotonga, Cook Islands since February 2025. DENV-1 and DENV-2 have both been reported. Please see our Topics in Brief article for further details on dengue.
Source: StateAs of 22 May 2025, the Cook islands Ministry of Health declared a dengue fever outbreak in Rarotonga. Seven locally acquired cases have been reported in the last 18 days. Please see our Topics in Brief article for further details on dengue.
Source: StateDengue in Tuvalu
As of 19 October 2025, a total of 782 dengue cases (with 230 confirmed) have been reported in Tuvalu since June 2025. The cases are widely distributed along Fongafale, Amatuku and three outer islands, Nanumaga (nine cases) Nukufetau (14 cases) and Vaitupu (one case). The outbreak is due to DENV-2. Please see our Topics in Brief article for further details on dengue.
As of 28 September 2025, a total of 213 confirmed dengue cases have been reported in Tuvalu since June 2025. Cases are distributed along Fongafale and two outer islands: Nanumaga and Nukufetau. DENV-2 serotype has been identified. Please see our Topics in Brief article for further details on dengue.
Source: SPCAs of 2 September 2025, a total of 131 confirmed dengue cases have been reported in Tuvalu since June 2025. DENV-2 serotype has been identified. Please see our Topics in Brief article for further details on dengue.
Source: SPCHIV in Fiji
A 2025 United Nations report has highlighted the dangers of unsafe practices amongst injecting drug users in Fiji and the contribution this has made in fuelling the sharp rise of new HIV infections. There has been a 10-fold increase in people living with HIV in Fiji between 2014 (500 cases) and 2024 (5,900 cases). Preliminary data from the Ministry of Health for 2024 shows around half of those receiving antiretroviral therapy contracted HIV through sharing needles. Please see the NHS information for further details on HIV.
Contaminated medicine in India
On 13 October 2025, the World Health Organization (WHO) published a Medical Product Alert about oral cold medicine in India contaminated with diethylene glycol (toxic to humans) linked to clusters of acute illness and deaths of children in India. These medicines are COLDRIF, Respifresh TR and ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals and Shape Pharma. These contaminated oral liquid medicines named in this alert are unsafe, pose a significant risk and can cause severe, potentially life-threatening illness. Their use, especially in children, may result in serious injury or death. Please see WHO Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicines for further details.
Extensively drug-resistant gonorrhoeae in Germany
As of 9 October 2025, a total of four locally acquired cases of extensively drug-resistant (XDR) Neisseria gonorrhoea were reported in 2025. A strong molecular connection was confirmed between three of these cases. All infections occurred in heterosexual adults living in the same geographical region of Germany, with no recent history of travel abroad. These are the first known locally acquired XDR/MDR Neisseria gonorrhoea cases in Germany. Please see UKHSA guidance on gonorrhoea for further details.
cVDPV1 in Laos
As of 16 October 2025, one circulating vaccine-derived poliovirus type 1 (cVDPV1) case was confirmed, with onset of paralysis on 3 September 2025, in Savannahket. This is the first case in Laos this year and is a new emergence. Please see our Topics in Brief article for further details on polio.
Chikungunya in Pakistan
As of September 2025, over 1,000 suspected cases of chikungunya have been reported in Pakistan during 2025. An increase in case numbers was noted between 4 May and 21 June 2025. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Somalia
An outbreak of chikungunya has been reported in Sool region, January – June 2025. A total of 488 suspected cases were recorded. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Indonesia
As of 31 July 2025, a total of 3,608 confirmed chikungunya cases have been reported across 19 provinces of Indonesia during 2025. This represents on increase in case numbers compared to the same period in 2024 when 1,399 cases were recorded. Please see our Topics in Brief article for further details on chikungunya.
NaTHNaC regularly review and update information on disease outbreaks and other health issues that may affect the UK traveller. You can search the information by disease or by country in our Outbreak Surveillance section.
The information comes from a wide variety of sources and can be used along with the Country Information section of our website where you will find recommendations on vaccines, malaria and other risks for each country (where relevant).
Please note that not all cases of disease or outbreaks are reported. In some countries, there may be limited surveillance and reporting processes in place so information can be difficult to obtain. Some diseases may only be reported if they occur outside of the usual recognised risk area or season, or they have been reported in greater than usual numbers. Outbreaks of those diseases included in the UK childhood vaccination programme are not usually reported unless the outbreak is unusual or unexpected.
The information presented in the disease surveillance reports is collated from a variety of sources, including government bodies, international organisations and the media. The verification status of each report is clearly indicated. Verified reports are confirmed by official sources. Some unverified reports are included to ensure timely dissemination of information and where possible we will try to substantiate these reports, although confirmation may not always be possible. Unverified reports may be subject to change, misreporting and may later prove to be unsubstantiated. They should not therefore be regarded as official.
Where available, a web link is provided to the original information source. We cannot accept responsibility for the sites to which it links, or for the information found on those sites. Linking to outside sites does not in any way imply endorsement of these sites. If you wish to use the following content for official purposes, please refer to the original sources of information.
Key to NaTHNaC alert level feature
LEVEL 1: GREEN |
Take usual precautions
|
Follow standard protective measures, as recommended for this destination, disease or situation. Be aware that advice may change and check for updates. |
|
LEVEL 2: AMBER |
Take extra precautions
|
Follow any additional precautions recommended. Be alert and check regularly for changes in advice about this ongoing situation. Advice may be relevant for all travellers or apply to a specific group of travellers. |
|
LEVEL 3: RED |
FCDO advise against travel
|
The Foreign, Commonwealth & Development Office (FCDO) advise against travel on health grounds. This may mean avoiding non-essential travel, or all travel, follow the FCDO advice for details. Please note we do not report on FCDO safety and security alerts. Travellers should check the FCDO travel advisories for their destination for this information. |
|
Alert categories are based on the situation at the time of publication. They will not be routinely updated unless outbreak information or a news item is updated.
Help us to adapt a Travel Health Resource for UK Travellers
Take part in a study that aims to help UK travellers make informed choices about Japanese encephalitis (JE) vaccination.
Find out moreGet TravelHealthPro on your site
Integrate features of TravelHealthPro into your own website with our API and widget
